Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
Crossref DOI link: https://doi.org/10.1186/s12964-016-0129-y
Published Online: 2016-02-24
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Halbach, Sebastian
Hu, Zehan
Gretzmeier, Christine
Ellermann, Julia
Wöhrle, Franziska U.
Dengjel, Jörn
Brummer, Tilman
Funding for this research was provided by:
José Carreras Leukämie-Stiftung (13/12)
Deutsche Forschungsgemeinschaft (GSC-4)
Deutsche Forschungsgemeinschaft (EXC 294)